| Project/Area Number |
26293374
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Yoshida Shigeo 九州大学, 医学(系)研究科(研究院), 准教授 (50363370)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
石橋 達朗 九州大学, 大学病院, その他 (30150428)
中尾 新太郎 九州大学, 大学病院, 助教 (50583027)
佐々 由季生 福岡大学, 医学部, 講師 (80580315)
池田 康博 九州大学, 医学(系)研究科(研究院), 准教授 (20380389)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2016: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Keywords | 糖尿病網膜症 / 加齢黄斑変性 / ペリオスチン / テネイシンC / 眼内増殖 / 分子標的薬 / 核酸医薬 / 薬物送達 / 網脈絡膜増殖 / 脈絡膜増殖組織 |
|---|
| Outline of Final Research Achievements |
In intraocular proliferative diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD), fibro (vascular) membrane (FVM) formation above and beneath the retina plays a pivotal role in the primary pathology. We have succeeded in extracting approximately 100 highly expressed genes in FVMs associated with PDR, which included periostin and tenascin-C, a matricellular protein.
We showed that the expression of periostin and tenascin-C was increased in the retinas of a mouse model of oxygen-induced retinal neovascularization (NV) and in choroidal NV. A new class of RNA interference (RNAi) agent that targets periostin and tenascin-C had a significant inhibitory effect on the retinal NV, CNV and choroidal fibrosis than control RNAi with no apparent adverse effects. These findings suggest a causal relationship between these matricellular proteins and intraocular FVM formation, and a potential therapeutic role of the new intravitreal RNAi agents for DR and AMD.
|
